Novo Nordisk’s investigational triple agonist, UBT251, has demonstrated a mean weight loss of 19.7% after 24 weeks in a Phase…
Read More

Novo Nordisk’s investigational triple agonist, UBT251, has demonstrated a mean weight loss of 19.7% after 24 weeks in a Phase…
Read More
The fundamental architecture of human memory relies on a sophisticated "division of labor" within the brain, according to a groundbreaking…
Read More
The pursuit of understanding the fundamental building blocks of matter has long been a quest defined by the limitations of…
Read More
In a significant development poised to reshape the competitive landscape of cancer therapeutics, global pharmaceutical giant MSD (known as Merck…
Read More
Since its inception in 1921, Science News has stood as a steadfast beacon of independent, nonprofit journalism, dedicated to delivering…
Read More
A groundbreaking discovery by a research team spearheaded by Universitat Autònoma de Barcelona (UAB) scientist David Reverter has unveiled the…
Read More
In a significant stride towards empowering individuals with greater control over their financial data, software engineer Shittu Olumide has developed…
Read More
In a recent clinical update featured on "This Week in Virology" (TWiV) episode 1290, Dr. Daniel Griffin provided a comprehensive…
Read More
The fundamental mechanics of animal movement have long been attributed to the microscopic interactions of proteins, but a groundbreaking study…
Read More
Salk Institute researchers have pinpointed a crucial protein, Med14, that acts as a molecular bridge connecting GLP-1 agonist drugs to…
Read More